Transgene SA
Cena
Kam míří tržby
Načítám tok výsledovky…
Odkud plynou tržby
Fundamenty
Načítám klíčová čísla…
Insideři, analytici a lidé
Všechny obchody a změnyNačítám insidery, analytiky a názory…
Co se právě děje
AI souhrnO společnosti
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Český popis připravujeme.
- Zaměstnanci
- 152
- Země
- Francie
- Data od
- 12. 4. 2000